Regeneron Pharmaceuticals (REGN) Receivables (2009 - 2026)

Regeneron Pharmaceuticals' Receivables history runs 18 years deep, the most recent figure standing at $5.7 billion for Q1 2026.

• In Q1 2026, Receivables rose 3.06% year-over-year to $5.7 billion; the TTM figure through Mar 2026 stood at $5.7 billion (up 3.06% YoY), while the FY2025 annual figure was $5.7 billion, down 7.58% from the prior year.
• Receivables was $5.7 billion for Q1 2026 at Regeneron Pharmaceuticals, roughly flat from $5.7 billion in the prior quarter.
• In the past five years, Receivables ranged from a high of $6.2 billion in Q4 2024 to a low of $4.8 billion in Q1 2022.
• Historically, Receivables has averaged $5.5 billion across 5 years, with a median of $5.6 billion in 2023.
• Biggest YoY gain for Receivables was 15.96% in 2022; the steepest drop was 26.25% in 2022.
• A 5-year view of Receivables shows it stood at $5.3 billion in 2022, then advanced by 6.35% to $5.7 billion in 2023, then increased by 9.61% to $6.2 billion in 2024, then decreased by 7.58% to $5.7 billion in 2025, then decreased by 0.18% to $5.7 billion in 2026.
• The last three Receivables figures came in at $5.7 billion (Q1 2026), $5.7 billion (Q4 2025), and $5.7 billion (Q3 2025), per Business Quant data.